-
Company Profile
Pharmacyclics LLC – Company Profile
Pharmacyclics LLC (Pharmacyclics), a subsidiary of AbbVie Inc, is a biopharmaceutical company which focuses on the development and commercialization of small-molecule medicines for the treatment of cancer and immune-mediated diseases. The company’s marketed product includes Imbruvica is an once-daily, first-in-class bruton's tyrosine kinase (BTK) inhibitor developed for the treatment of patients with chronic lymphocytic leukemia, waldenstrom's macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma and chronic graft-versus-host disease. Its products candidate in clinical development includes Imbruvica BTK inhibitor intended for the...
Add to Basket -
Sector Analysis
B-Cell Non-Hodgkin’s Lymphoma (NHL) – Opportunity Analysis and Forecasts to 2027
Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of proliferative malignancies that arise in the B cells, T cells, or natural killer (NK) cells within the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen. B-cell lymphomas comprise approximately 85% of all NHL cases diagnosed in the US, and are a diverse group of blood cancers that arise in the B-cells. This report focuses on the four NHL subtypes that represent the greatest commercial opportunities for drug developers...